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Pseudomonas  aeruginosa has an inducible, naturally
occurring cephalosporinase that confers low-level resistance
to aminopenicillins and narrow-spectrum cephalosporins
such as cephalothin and cefoxitin (1). Resistance to extended-
spectrum cephalosporins may arise from overexpression of
this cephalosporinase, acquired beta-lactamases, or both (1).
The acquired beta-lactamases may be either clavulanic-acid
inhibited (mostly Ambler class A enzymes) or clavulanic-acid
resistant (class B and class D enzymes) (2). The class A
extended-spectrum beta-lactamases (ESBLs) may derive
from narrow-spectrum beta-lactamases of TEM and SHV
types, as extensively reported for Enterobacteriaceae and
rarely for P. aeruginosa (2). Other class A enzymes reported in
P. aeruginosa include PER-1, which we first identified as
chromosomally located and which is widespread in
P. aeruginosa isolates in Turkey (11% of the hospital isolates)
(3,4). Lately, another class A ESBL integron-located gene,
blaVEB-1, has been identified from P. aeruginosa and
enterobacterial isolates from Southeast Asia (5-7).
We report on two novel VEB-1-like beta-lactamases from
P. aeruginosa clinical isolates from Kuwait. This is the first
report of extended-spectrum enzymes from nosocomial
isolates from this part of the world.
The Study
P. aeruginosa KU-1 was isolated in January 1999 at Ibn
Sina Hospital in Kuwait from endotracheal secretions of a 1-
day-old infant with respiratory tract infection, hospitalized in
the intensive care unit (ICU) unit because of severe
enterocolitis. He was first treated with cefotaxime, amikacin,
and metronidazole. These antibiotics were discontinued, and
he was given imipenem. He improved and was discharged 7
days later. As it was a single isolate of a multidrug-resistant
strain, isolation precautions were carried out only in the
neonatal ICU. The infant’s mother could not remember
whether she had received antibiotic therapy during her
pregnancy (which was uneventful). She had not traveled
outside Kuwait.
P. aeruginosa KU-2 was also isolated in June 1999 from
the urine of a 73-year-old man admitted to the ICU of another
Kuwaiti hospital, Mubarak Al-Kabeer, with ischemic chest
pain and bronchectiasis. On day 2 of his hospitalization, fever
developed, but blood and urine cultures were negative. He
was treated with ceftazidime for 12 days beginning on day 2.
During his hospital stay, hematuria developed, followed by
urine retention. On day 28, pus from a urinary catheter
infection after transurethral prostatitic surgery grew
P. aeruginosa KU-2 that was susceptible to norfloxacin.
P. aeruginosa KU-2 was the only P. aeruginosa strain isolated
from this patient’s clinical specimens. He was treated with
norfloxacin. Repeated urine cultures did not yield any
organism, and he was discharged 15 days later. He had no
history of travel outside Kuwait.
Strains from both patients were identified by using an
API-20 NE system (Biomerieux, Marcy-l’Etoile, France).
Preliminary antibiotic susceptibility testing by disc diffusion
(5) revealed a slight synergy between ceftazidime- and
clavulanic acid-containing discs for two clinical isolates,
P. aeruginosa KU-1 and KU-2. Susceptibility testing of beta-
lactams for P. aeruginosa KU-1 and KU-2 was then performed
by a Mueller-Hinton agar dilution method (8). Both strains
showed decreased susceptibility to all beta-lactams except
imipenem and piperacillin/tazobactam (Table). MICs of
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Table. MICs of beta-lactams for Pseudomonas aeruginosa KU-1 and
KU-2 clinical isolates, P. aeruginosa PU21(pROT-1), and PU21
reference strain
MICs (mg/L)
 P. aeru-
P. aeru- P. aeru-   ginosa P. aeru-
 ginosa  ginosa    PU21  ginosa
Antibiotica   KU-1   KU-2 (pROT-1)   PU21
Amoxicillin >512 >512 >512 64
Ticarcillin >512   512   512 16
Ticarcillin+CLA     64     16     16 16
Piperacillin     64     16     16   2
Piperacillin+TZB     32       8       8   1
Ceftazidime   512   512   512   0.25
Ceftazidime+CLA     16       8       8   0.25
Ceftazidime+TZB       8       4       8   0.50
Cefotaxime   512   128   128   4
Cefotaxime+CLA     64     16     16   2
Imipenem       2       2       2   0.12
Aztreonam >512 >512   512   0.5
Aztreonam+CLA     64       8       8   0.5
aCLA: clavulanic acid at a fixed concentration of 2 mg/L; TZB: tazobactam at a
fixed concentration of 4 mg/L.Dispatches
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ceftazidime were decreased by addition of clavulanic acid and
tazobactam, indicating the presence of a clavulanic-acid
inhibited ESBL (Table). According to antibiotic susceptibility
testing by Mueller-Hinton agar disc diffusion, P. aeruginosa
KU-1 and KU-2 were also resistant to aminoglycosides
(amikacin, gentamicin, netilmicin, tobramycin), chloram-
phenicol, tetracyclines, sulfonamides, and fluoroquinolones
(except for KU-2).
Beta-lactamase extracts from cultures of P. aeruginosa
KU-1 and KU-2 were obtained (8). Isoelectric focusing
analysis (8) revealed beta-lactamases with isoelectric points
of 7.4 and 8-8.4, the latter likely corresponding to
P. aeruginosa AmpC cephalosporinases. Whole-cell DNAs of
P. aeruginosa KU-1 and KU-2 were then obtained (3).
Preliminary polymerase chain reaction (PCR) experiments
were performed with DNAs of P. aeruginosa KU-1 and KU-2
as templates and primers specific for the following class A
beta-lactamases: TEM, SHV, CARB (PSE-1), GES-1, PER-1,
and VEB-1 (3,5,9-11). Only PCR using internal primers for
blaVEB-1 gave a positive result with an identical 642-bp
fragment. External blaVEB-1 specific primers gave 1,070-bp
PCR fragments with DNAs of both P. aeruginosa strains as
templates that were sequenced on both strands (6). The
deduced amino acid sequences, obtained over the internet (8),
identified VEB-1-like sequences that shared 99% amino acid
identity with VEB-1 (Figure).  Compared with VEB-1, the
amino acid changes in VEB-1a and VEB-1b from
P. aeruginosa KU-1 and KU-2, respectively, occurred in the
putative leader peptide sequence (Figure). Thus, the
hydrolytic activity of VEB-1a and VEB-1b should be identical
to that reported for VEB-1 beta-lactamase (5).
The genetic background of blaVEB-1a and blaVEB-1b was
further characterized. Plasmid extraction, conjugation, and
electroporation experiments were performed (8). A plasmid
(pROT-1) of ca. 70 kb carrying blaVEB-1a gene was identified
according to hybridization results by using an internal PCR-
obtained probe for blaVEB-1 (5). Plasmid pROT-1 was self-
conjugative from P. aeruginosa KU-1 to in vitro obtained
rifampin-resistant P. aeruginosa PU21 reference strain after
selection of transconjugants onto Mueller-Hinton agar plates
each containing 150 µg/mL rifampin and 200 µg/mL
ticarcillin. As assessed by antibiotic susceptibility testing by
disc diffusion, plasmid pROT-1 conferred additional
resistance to gentamicin, netilmicin, sulfonamides, and
tobramycin. MICs of beta-lactams for P. aeruginosa PU21
(pROT-1) mirrored those obtained for P. aeruginosa KU-1
(Table). While the plasmid location of blaVEB-1 gene is known
only in Enterobacteriaceae (5-7), its report in P. aeruginosa
may signal the evolution of its spread. The blaVEB-1b  gene was
not plasmid located, but a PCR-obtained 642-bp internal
probe for blaVEB-1 hybridized at chromosomal position of
whole-cell DNA of P. aeruginosa KU-2.
The blaVEB-1 gene is located on different structures of
class 1 integrons (5-7). Integrons comprise two conserved
regions (5'-CS and 3'-CS) flanking an internal variable region
usually containing several gene cassettes (13). Integrons are
in fact expression vectors for antibiotic resistance genes that
are included as gene cassettes and are neighbored (13). By
using primers located either in the 5'-CS sequence and the 5'
end of blaVEB-1 or in the 3' end of blaVEB-1 and the 3'-CS
sequence (5,14), PCR amplification experiments were
performed with whole-cell DNAs of P. aeruginosa KU-1 and
KU-2 as templates. In one case (strain KU-1), a PCR fragment
was obtained by using blaVEB-1 and 5'-CS primers, indicating
that blaVEB-1a was located downstream of a class 1 integrase
gene. In this case, the 4-kb PCR fragment differed from those
of known blaVEB-1 containing integrons identified in
Escherichia coli and P. aeruginosa isolates (5-7). Amplimers
of 1 kb were obtained for both strains using blaVEB-1 and 3'-CS
primers, showing that the 3'-CS end was present in both cases
and that the blaVEB-1-like sequences were located next to the
3'-CS end within class 1 integrons. The attC (59-be)
recombination sites (15) located downstream of gene cassettes
were identical for blaVEB-1a and blaVEB-1b to those described for
blaVEB-1 in P. aeruginosa and enterobacterial isolates
identified so far from Southeast Asia (5-7). Therefore, an
identical blaVEB-1-like gene cassette may be located on
different class 1 integrons. Using 5'-CS and 3'-CS primers,
two additional PCR fragments were obtained for
each  P. aeruginosa strain, showing that both strains
contained another blaVEB-negative class 1 integron.
For  P. aeruginosa KU-1, a 950-bp PCR fragment for an
aadA1a gene coding for an aminoglycoside modifying enzyme
was found to be plasmid- and integron-located in Salmonella
enterica serotype Typhimurium (16). For P. aeruginosa KU-2,
a 500-bp PCR fragment encoding a putative 95 amino acid
protein of unknown function was PCR amplified. It shared
71% amino acid identity with an amino acid sequence from a
gene that was Tn1696 transposon-located and In4 integron-
located in P. aeruginosa (17).
Finally, P. aeruginosa KU-1 and KU-2 isolates containing
VEB-1-like beta-lactamases were compared with VEB-1
positive P. aerugionosa strain JES from Thailand by using
random amplified polymorphic DNA technique (10,18). The
isolates were not clonally related (data not shown). Although
the patients had not traveled outside Kuwait, introduction of
P. aeruginosa into Kuwaiti hospitals by travelers or patients
from Southeast Asia cannot be ruled out.
Conclusions
The presence of clavulanic-acid inhibited ESBLs in
P. aeruginosa isolates may account for part of the 50%
resistance to ceftazidime of P. aeruginosa strains isolates
from ICUs in Kuwait (19). ESBLs in P. aeruginosa in Kuwait
Figure. Comparison of the amino acid sequence of VEB-1, VEB-1a,
and VEB-1b beta-lactamases from Pseudomonas aeruginosa JES
from Thailand and KU-1 and KU-2 from Kuwait. Dashed lines
indicate identical amino acids. Arrow indicates position of the
putative cleavage site of the peptide leader. Numbering is according
to Ambler designation (12).Dispatches
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and other Middle Eastern hospitals may be underestimated
because routine detection with a double disc synergy test may
be difficult. Identification of ESBLs is of interest since they
confer resistance to all extended-spectrum cephalosporins
and aztreonam, whatever their MICs. This has been
confirmed by experimental data using a model of pneumonia
in rats with the Ambler class A ESBL, PER-1 (20).
This work underscores that very similar ESBLs may be
identified in different parts of the world. It is the first report
of ESBL genes characterized from P. aeruginosa isolates from
the Middle East.
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